Background: In addition to passive immunotherapy using anti-HER2 monoclonal antibodies, active immunotherapy via HER2 targeting is an interesting approach to inducing specific anti-tumor immune responses. We have recently reported the immunogenicity of HER2 subdomains following DNA immunization and HER2 protein boosting. In the present study, we evaluated the immunogenicity of different HER2 ex...

Background: Human epidermal growth factor receptor 2 (HER2) has a crucial role in several malignancies. The extracellular domain of HER2 (HER2-ECD) has been extensively employed as an important target in passive and active immunotherapy. Isolated recombinant prokaryotic HER2-ECD subdomains were previously found to be ineffective in inducing anti-tumor antibody response. Objective: To employ rec...

results isotype of 1f1 clone was determined to be igg1, which reacted with native protein in the western blot experiment and stained 20% of the membrane of neoplastic cells overexpressing her2 with 3+ grade. however, 3l5 clone showed a low reaction (10%) with native her2 in immunohistochemistry. conclusions the results of both western blotting and immunohistochemistry showed that native her2 ca...

Background: Human epidermal growth factor receptor 2 (HER2) is overexpressed in several human malignancies and numerous studies have indicated that it plays important roles in the development and maintenance of the malignant phenotype. Targeting of HER2 molecules with monoclonal antibodies (mAbs) is a promising therapeutic approach. However, anti-HER2 mAbs affect cancer cells differently, depen...

HER2 plays an important role in the development and maintenance of the malignant phenotype of several human cancers. As such, it is a frequently pursued therapeutic target and two antibodies targeting HER2 have been clinically approved, trastuzumab and pertuzumab. It has been suggested that optimal inhibition of HER2 is achieved when utilizing two or more antibodies targeting nonoverlapping epi...

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family of receptor tyrosine kinases that play important roles in all processes of cell development. Their overexpression is related to many cancers, including examples in the breast, ovaries and stomach. Anticancer therapies targeting the HER2 receptor have shown promise, and monoclonal antibodie...

Figure 1. Target domains for combined receptor blockade of HER2. Left, HER2 has an extracellular domain (ECD), a single transmembrane domain (TM), and a cytoplasmic kinase domain (CD). The dimerization loop of HER2 is indicated by the dashed circle, and small green circles indicate segments for which the crystal structures have not yet been solved. On the upper right is a space-filling model of...

background: one million people are diagnosed with gastric cancer (gc) annually and the prognosis for patients with advanced gc or gastroesophageal junction (gej) cancer is usually poor with a median survival time of 8 to 10 months. recent reports have identified that anti her2 target therapy improved the median survival rate in patients with her2 positive gc; but a wide range of her2 overexpres...

introduction: her2/neu, a member of the epidermal growth factor receptor family, has been shown to be over-expressed in some tumors. the purpose of this study was to determine the salivary levels and tissue expression of her2/neu in patients with head and neck squamous cell carcinoma (hnscc) and their correlation with clinicopathologic parameters.   materials and methods: enzyme-linked immunoso...

Background: Amplification of HER2 is seen in 20-30% of breast cancer cases. Measurement of HER2 gene amplification appears to be of vital importance in planning the treatment schedule for patients with breast carcinoma. The aim of our study was to evaluate HER2 amplification status in malignant and benign breast tumors by differential PCR (dPCR). Materials and Methods: The genomic DNA was ex...